<DOC>
	<DOCNO>NCT00394381</DOCNO>
	<brief_summary>A phase I/II study explore feasibility efficacy autologous CIK cell patient acute myeloid leukemia ( AML ) / high grade myelodysplastic syndrome ( MDS ) 1 . Group 1 : As adjuvant therapy minimal residual disease state autologous PBSCT . 2 . Group 2 : As adoptive immunotherapy untreated disease state conventional therapy curative intent applicable</brief_summary>
	<brief_title>Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>This Phase I /II study feasibility / efficacy adoptive immunotherapy autologous CIK cell follow 2 group patient AML high grade MDS : 1 . Group 1 patient minimal residual disease state post autologous peripheral blood stem cell transplant ( PBSCT ) , 2 . Group 2 patient untreated high grade MDS AML , fit standard curative intent chemotherapy . The CIK cell generate leukapheresis patient culture GMP facility . Four repeated infusion give target dose 1x10e10 T cell per infusion . Efficacy assess 1 . Disease free survival compare historical control group 1 give CIK cell post autologous PBSCT adjuvant immunotherapy ( n=20 3 year ) , 2 . Effect peripheral marrow leukemia cell load group 2 patient give CIK cell alternative therapy place chemotherapy ( n=10 ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . For Group 1 : AML MDS post autologous peripheral blood marrow stem cell transplant . 2 . For Group 2 : High grade MDS ( RAEB RAEBIT ) AML , haematologist charge assess deem unfit chemotherapy curative intent.Patients must fairly stable white cell count require low dose myelosuppressive medication 3 . Patients must understand trial nature treatment accept possible absence benefit . 1. uncontrolled infection 2. life expectancy le 6 week . 3 . Contraindication undergo one session leukapheresis PBMNC harvesting</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>autologous CIK cell</keyword>
	<keyword>autologous peripheral blood stem cell transplant</keyword>
</DOC>